TruScreen Passes CFDA Technical Assessment for its Second Generation Device in China

Published: 24 November 2017

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to advise that the CFDA has posted on its website that TruScreen has passed Chinese Food and Drug Administration (CFDA) technical assessment and its file has proceeded to the final stage of the approval process. The final culmination of this process would be the formal issuing of the approval certificate.



For more information visit or contact

Martin Dillon, TruScreen Chief Executive
Officer, eMail:

Media Liaison, Jackie Ellis
Phone: +64 27 246 2505

About TruScreen:

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection